After bringing groundbreaking treatment advancements to oncology, CAR T therapies are beginning to show promise in additional therapeutic areas. As these advanced therapies enter clinical trials in new patient communities, successful programs rely on understanding which elements of the oncology construct can be seamlessly applied in the new paradigm.
In this webinar, panelists will discuss how the collaboration between therapeutically aligned teams impacts study delivery for CAR T in autoimmune disease and neurology clinics. Discussions will include considerations for sponsor, site, and patient stakeholders. Don’t miss this chance to learn from the successful implementation of CAR T trials and to ask the panelists your own questions.
Speakers
Dr. Simran Padam, MD, Medical Director, Medical Affairs, Hematology, Oncology, & Rare Disease, Worldwide Clinical Trials
Dr. Simran Padam is the CAR T Medical Advisor at Worldwide Clinical Trials, and she has extensive experience in global Phase I – III clinical research. She is an active member of the American Society of Clinical Oncology, European Society for Medical Oncology and the American Society of Hematology. She has authored 15 peer-reviewed publications and has presented at numerous conferences and lectures.
Dr. Amy Raymond, PhD, PMP, Executive Director, Therapeutic Strategy Lead, Rare Disease & Cellular and Genetic Medicines, Worldwide Clinical Trials
Dr. Amy Raymond has been a drug discovery and development professional for over 25 years, including progressive roles in clinical operations and clinical strategy, and today leads the Cell & Gene Therapy Hub at Worldwide. Her clinical development experience has focused on rare and complex diseases, especially development of cell and gene therapies. Amy completed her doctoral training in molecular biology at University of California San Diego and post-doctoral training in molecular biology at Memorial Sloan-Kettering.
Nathan Chadwick, Senior Director, Therapeutic Strategy Lead, Rare Disease, Worldwide Clinical Trials
With more than a decade of dedicated experience in clinical research, Nathan Chadwick is well-versed in several therapeutic areas, with a specialized focus in neurology and rare disease. At Worldwide, Nathan is at the forefront of therapeutic strategy for rare disease, leading ongoing efforts with rare disease patient advocacy organizations while working to expand rare disease opportunities, studies and initiatives.
Chris Jenkins, Founder, CEO, Sabai
More info coming soon…
Dr. Tahseen Mozaffar, Professor of Neurology, Orthopaedic Surgery and Pathology and Laboratory Medicine, University of California, Irvine (UCI)
Dr. Tahseen Mozaffar is a Professor of Neurology, Orthopaedic Surgery and Pathology and Laboratory Medicine at University of California, Irvine (UCI). He is the Director of the UC Irvine-MDA ALS and Neuromuscular Center and the Director of the Division of Neuromuscular Diseases. Dr. Mozaffar serves as chair of one of the biomedical committees and the institutional liaison for Trials Innovation Hub for the Center for Translational Sciences Award (CTSA) at UCI. He is also the site PI and the senior author for the paper for the first CAR-T cell therapy trial in Myasthenia Gravis and study PI for the CABA-MYO myositis CAR-T trial.
Who Should Attend?
This webinar will benefit Vice Presidents, Directors, Managers, Department Heads, Scientists and Researchers working at pharmaceutical and biotechnology companies and those in the following fields:
- Clinical affairs
- Clinical R&D
- Clinical research
- Clinical operations
- Medical affairs
- Project management
- Regulatory affairs
- Strategic planning
What You Will Learn
Attendees will learn about:
- Applying best practices from oncology CAR T oncology trials
- Key elements for optimizing study start-up
- Operationalizing CAR T trials across specialty clinics at the site
- Patient journey, education and safety considerations
Xtalks Partner
Worldwide Clinical Trials
Worldwide Clinical Trials (Worldwide) is a leading global contract research organization (CRO) that works in partnership with biotechnology and pharmaceutical companies to create customized solutions that advance new medications, from discovery to reality. Our full-service clinical development capabilities include bioanalytical laboratory services and Phase I-IV clinical trials, as well as post-approval and real-world evidence studies – all powered by our talented and accessible team of clinicians, scientists, and researchers who bring their first-hand expertise to each clinical program.
At Worldwide, we understand that each customer and project are unique, so we take a collaborative and personalized approach to identify and meet specific needs and goals. Anchored in our company’s scientific heritage, we are therapeutically focused on cardiovascular, metabolic, neuroscience, oncology, and rare diseases. We apply this deep therapeutic knowledge to develop flexible plans and quickly solve problems in the rapidly evolving clinical development landscape.
Our team of 3,000+ professionals spans 60+ countries, and believes that through collaboration, and a culture that embraces diversity, equity, inclusion, and belonging (DEI&B), everyone plays an important role in making a world of difference for patients and their caregivers. We are united in cause with our customers to improve the lives of patients through new, innovative therapies.
For more information, please visit www.worldwide.com or connect with us on LinkedIn.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account